Skip to main content
Watch Insiders
CTNMHealthcare

Contineum Therapeutics Inc (CTNM) Insider Trading

In the last 90 days, 1 Contineum Therapeutics Inc (CTNM) insider reported no open-market purchases and 2 sales totaling $81,171. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 8, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 8, 2026Carmine N. StengoneCEO and PresidentSale2,500$16.46$41,142
Aug 3, 2026Carmine N. StengoneCEO and PresidentSale2,500$16.01$40,029
Jul 9, 2026Daniel S. LorrainChief Scientific OfficerSale1,040$16.00$16,640
Jul 8, 2026Carmine N. StengoneCEO and PresidentSale2,500$16.00$40,000
Jul 1, 2026Daniel S. LorrainChief Scientific OfficerSale37,179$15.99$594,578
Jun 30, 2026Tim WatkinsCMO & Head of DevelopmentSale10,833$16.02$173,590
Jun 30, 2026Carmine N. StengoneCEO and PresidentSale10,000$16.01$160,080
Jun 1, 2026Daniel S. LorrainChief Scientific OfficerSale4,170$13.16$54,862
May 1, 2026Daniel S. LorrainChief Scientific OfficerSale4,170$13.12$54,694

Common questions

CTNM insider trading FAQ

Are CTNM insiders buying or selling?
Over the last 90 days, CTNM insiders were net sellers, reporting $0.00 of open-market purchases and $81,171 of sales.
When was the last CTNM insider purchase?
No open-market insider purchase of Contineum Therapeutics Inc stock was reported in the last 90 days.
Where does CTNM insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Contineum Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.